They say good things come in small packages. Like Herve Villechaize, the French actor who played Tattoo on Fantasy Island. The idiom also applies to drugs. No, we’re not talking about the little envelope that Nick at work slips you in the breakroom every other Friday. This is about nano drug delivery – using nanoparticles […]
If you’re lucky enough to raise funding for your startup, you will then need to contend with new stakeholders that want to see “an exit”. When we refer to an exit, we refer to an event that takes place where the investors who gave you money, then get their money back – ideally, more money than they gave you […]
It’s hard to say just how many publicly traded stocks we’ve covered so far on Nanalyze, but we’d guess that around 40% of our articles involve a publicly traded stock that has some degree of exposure (or claimed exposure) to one or more emerging technologies. If we take out all the over the counter (OTC) […]
At the CB Insights fintech conference that wrapped up recently, an interesting fellow named Michael Novogratz made the remark that “Great bubbles occur around stories that are going to happen“, and we thought that would pretty appropriately describe the little hype bubble that took place around 2004 for nanotechnology. We had some forums at that […]
Nanotechnology was all the rage back in 2004 when George Dubya Bush signed the Nanotechnology Research and Development Act and investors caught wind of a potential opportunity. This, of course, prompted us to start Nanalyze as we were dying to figure out how we could get a piece of that nano action as retail investors. […]
For a majority of the people in this world who were fortunate enough to receive vaccinations, there are probably still some lingering unpleasant memories of being stuck with needles as a child. One Australian startup, Vaxxas, promises to eliminate the need for needles to be used in vaccinations by using their “Nanopatch” application method. About […]
In August of last year, we highlighted a nano drug delivery company called BIND Therapeutics (NASDAQ:BIND), a company with strong pharma partnerships and an experienced management team. While BIND Therapeutics hit a 52-week low this week, about one-third of the way through today’s trading day we see that BIND is up over +11% with volume […]
The U.S. market for branded prescription drugs for acne was estimated to be approximately $2.6 billion for the 12 months ended March 31, 2014, of which $1.6 billion was attributed to topical drugs such as Epiduo and Aczone and $1 billion was attributed to oral drugs. Orally administered Solodyn is the brand name for an antibiotic […]
In a previous article, we discussed Bind Therapeutics (NASDAQ:BIND), a company developing a nano-drug delivery technology for Docetaxel, one of the most commonly used cancer chemotherapy drugs approved for breast cancer, head and neck cancer, and gastric cancer. Another company we highlighted, Oasmia (STO:OASM), is doing much the same thing. One company with a nano-drug delivery platform looking to […]
RNA Interference (RNAi) is a new approach in the development of specific targeted therapies against both rare diseases and cancer. Historically, the pharmaceutical industry has developed two fundamental classes of drugs that can address well-defined targets: small molecules and antibodies. Both of these drug classes have been very successful but are limited in the nature of the […]